• Product name
    Anti-Bcr-abl antibody [7C6]
    See all Bcr-abl primary antibodies
  • Description
    Mouse monoclonal [7C6] to Bcr-abl
  • Host species
  • Specificity
    ab187831 recognizes an epitope within the amino acid sequence SSINEEITPRRQS of Bcr/Abl.
  • Tested applications
    Suitable for: IHC-P, ICC/IF, IP, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Bcr-abl. The exact sequence is proprietary. (Bcr686 thyroglobulin conjugate)


    Database link: A9UFO7

  • Epitope
    Cells from immunized Balb/c mice were fused with the P3X63Ag8 myeloma cell line.
  • Positive control
    • WB: K562 cell lysates. ICC/IF: K562 cells. IHC-P: Human hepatocarcinoma, human breast carcinoma and mouse liver tissue. IP: K562 whole cell lysate.



Our Abpromise guarantee covers the use of ab187831 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/200.
ICC/IF 1/50 - 1/100.
IP Use at an assay dependent concentration.
WB 1/500 - 1/1000. Predicted molecular weight: 197 kDa.


  • Relevance
    The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukemia (CML) and in a proportion of cases of acute lymphocytic leukemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9 and results in the production of a chimaeric BCR-ABL protein with enhanced kinase activity. These antibodies may be useful for studies of the oncogene and have potential diagnostic and prognostic applications.
  • Database links
  • Alternative names
    • ALL antibody
    • BCR ABL fusion antibody
    • BCR ABL fusion protein antibody
    • BCR antibody
    • BCR/ABL fusion antibody
    • BCR/ABL fusion protein antibody
    • Bcr/c abl oncogene protein antibody
    • BCRe18/ABL1e3 fusion protein antibody
    • Breakpoint cluster region antibody
    • CML antibody
    see all


  • Immunocytochemistry/Immunofluorescence analysis of K562 cells labelling Bcr-able (green) with ab187831. Cells were fixed with formalin and permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature. Cells were blocked with 1% blocker BSA for 15 minutes at room temperature. Cells were incubated with the primary antibody at a dilution of 1/50 for 1 hour at room temperature, washed with PBS, and incubated with a DyLight 488-conjugated goat anti-mouse IgG secondary antibody. Nuclei (blue) were stained with Hoechst 33342 dye. Images were taken at 20X magnification.

  • Immunoprecipitation of BCR-ABL and BCR was performed using K562 whole cell lysate. Antigen-antibody complexes were formed by incubating 800 µg of lysate with 5 µg of ab187831 overnight on a rocking platform at 4°C. The immune complexes were captured on 50 µl Protein A/G Agarose, washed extensively, and eluted. The sample was resolved on a 4-20% Tris-HCl polyacrylamide gel, transferred to a PVDF membrane, and blocked with 5% BSA/TBS-0.1% Tween for 1 hour. The membrane was probed with a phosphotyrosine monoclonal antibody (detecting p-Tyr-BCR-ABL/p-Tyr-BCR) at a dilution of 1/1000 overnight rotating at 4°C, washed in TBST, and probed with a goat anti-mouse IgG-HRP secondary antibody at a dilution of 1/20,000 for 1 hour. Chemiluminescent detection was performed.



This product has been referenced in:
  • Zhang C  et al. Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells. Oncol Lett 13:2059-2070 (2017). WB . Read more (PubMed: 28454362) »

See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab187831.
Please use the links above to contact us or submit feedback about this product.


Sign up